Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Author's Avatar
Nov 07, 2019
Article's Main Image

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of inducement awards to its Chief Medical Officer, Luisa M. Stamm, MD, PhD on November 6, 2019.